ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 16, 2019

Two poster presentations on ARQ 751 will highlight data from the phase 1 trial, as well as preclinical studies demonstrating the potential of ARQ 751 in combination with various therapeutic agents

BURLINGTON, Mass.--(BUSINESS WIRE)--Oct. 16, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting data on the company's AKT inhibitor, ARQ 751, in two poster presentations at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held from October 26th to October 30th, 2019 in Boston, Massachusetts.

Presentations will detail clinical data demonstrating the correlation between biomarkers and patient response to treatment with ARQ 751 as well as preclinical *in vivo* and *in vitro* findings supporting the potential of ARQ 751 in combination with a variety of therapeutic agents.

Details on the presentations are as follows:

Presentation Title: The use of biomarkers and ctDNA in a phase 1 trial of ARQ 751
Abstract Number: A034
Presenter: Shubham Pant, M.D., MD Anderson Cancer Center
Date: October 27, 2019
Poster Viewing Time: 12:30 p.m.- 4:00 p.m. EDT
Location: Hall D, Hynes Convention Center

Presentation Title: *In vitro* and *in vivo* combination of ARQ 751 with PARP inhibitors, CDK4/6 inhibitors, Fulvestrant and Paclitaxel
Abstract Number: C076
Presenter: Yi Yu, Ph.D., ArQule
Date: October 29, 2019
Poster Viewing Time: 12:30 p.m.- 4:00 p.m. EDT
Location: Hall D, Hynes Convention Center

Additional details can be found on the conference website. A copy of presentation materials can be accessed by visiting the Publications & Presentations section of the ArQule website after the presentations conclude.

About ARQ 751
ARQ 751 is orally bioavailable, selective small molecule inhibitor of the AKT serine/threonine kinase. The AKT pathway when abnormally activated is implicated in multiple oncogenic processes such as cell proliferation and apoptosis. This pathway has emerged as a target of potential therapeutic relevance for compounds that inhibit its activity, which has been linked to a variety of cancers as well as to select non-oncology indications.

About ArQule
ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule's mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of four drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule's pipeline includes: ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant BTK, in phase 1/2 for patients with B-cell malignancies refractory to other therapeutic options; miransertib (ARQ 092), a potent and selective inhibitor of the AKT serine/threonine kinase, in a registrational trial with cohorts in Proteus syndrome and PROS; ARQ 751, a next generation highly potent and selective AKT inhibitor, in phase 1 for patients with solid tumors with AKT1 and PI3K mutations; and derazantinib, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in a registrational trial for iCCA in collaboration with Basilea and Sinovant. ArQule's current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company's proprietary library of compounds.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191016005130/en/

Source: ArQule, Inc.

Corporate:
Kathleen Farren
Investor Relations & Executive Assistant to the CFO
ir@arqule.com

Media:
Cait Williamson, Ph.D.
LifeSci Public Relations
(646) 751-4366

cait@lifescipublicrelations.com